| Literature DB >> 36210873 |
Niloofar Khoshnam-Rad1, Marsa Gholamzadeh2, Mehrnaz Asadi Gharabaghi3, Shahideh Amini1.
Abstract
Background and Aim: The COVID-19 pandemic forced healthcare systems to apply new technology-based solutions. The main objective of our study was to describe the conceptual model for rapid implementation of telepharmacy service and the main steps that should be considered. Method: In response to a limited number of on-site clinical pharmacy specialists and a lack of technology infrastructure, a cross-sectional telepharmacy program was established to support major teaching hospitals. A store and forward model of teleconsultation was employed using WhatsApp messenger to cover various aspects of multidisciplinary collaboration in COVID-19 management. All identifiable personal information was removed from all exchanged messages of collaborative consultations. The thematic analysis of consultations was performed to extract the main themes and subthemes that should be considered for designing future telepharmacy systems.Entities:
Keywords: COVID‐19 pandemic; clinical pharmacy; clinical pharmacy expansion model; critical care; telemedicine; telepharmacy
Year: 2022 PMID: 36210873 PMCID: PMC9528958 DOI: 10.1002/hsr2.851
Source DB: PubMed Journal: Health Sci Rep ISSN: 2398-8835
Figure 1The telepharmacy consultation model (In this model, physicians and nurses from two different hospitals [red and blue teams]) can share clinical information and patient records (yellow arrows) with a clinical pharmacist through telemedicine tools. After careful evaluation of the case and reviewing the latest information, the appropriate medication management considering the patient's condition (green arrows) will be shared by the clinical pharmacist, and the patient benefits from it
Figure 2Themes and subthemes of clinical pharmacist interventions to ensure the safe and effective use of drugs. Themes are shown on left in rectangular shapes, and subthemes are shown on right in oval shapes
Examples of different scopes of interventions of critical care pharmacists in the COVID‐19 pandemic in our center
| Scope of the intervention | Examples |
|---|---|
| COVID‐19 management |
Providing and updating information about the appropriate use of repurposed drugs for COVID‐19 |
|
Providing and updating information about disinfectants | |
|
Evaluating indications or contraindications to repurposed drugs for each patient | |
|
Providing information about the appropriate use of anticoagulants in COVID‐19 | |
|
Acting as principal investigator or coinvestigator of research teams for conducting clinical trials | |
|
Deciding about symptomatic treatment (cough, diarrhea, fever, etc.) | |
| Nutritional support |
Estimating required daily calories for patients and deciding about pharmaco‐nutrition and source of nutrition support |
|
Providing consultation about the enteral or parenteral route of nutrition | |
|
Consulting about the possible interaction between nutritional support and prescribed drugs | |
|
Consulting about drug administration via nasogastric tube | |
|
Providing information about vitamin and mineral supplementation in the management of COVID‐19 | |
| Pain, agitation, and delirium management |
Deciding on the selection of appropriate analgesics, anxiolytics, or antipsychotics |
|
Management of side effects of analgesics, anxiolytics, or antipsychotics | |
|
Management of drug‐drug interactions | |
|
Differentiating drug side effects (e.g., respiratory depression, tachycardia) with symptoms of COVID‐19 disease or anxiety | |
|
Appropriate use of opioids for the management of cough besides the pain control | |
| Antimicrobial management |
Providing information about the appropriate use of repurposed antibiotics for COVID‐19 |
|
Preventing antibiotic misuse and overuse | |
|
Conduct and translate research on all areas of antimicrobial resistance and antimicrobial stewardship | |
|
Management of side effects and interactions | |
|
Providing solutions for drug shortage | |
|
Therapeutic drug monitoring and appropriate dose adjustment | |
|
Appropriate drug for super‐infections and co‐infections | |
|
Evaluating efficacy and toxicities | |
| Individualized therapeutic adjustment |
Evaluating kidney and liver function and adjusting the dose of drugs accordingly |
|
Providing plans for preventing toxicity in patients with multiorgan failure | |
|
Dose adjustment based on augmented renal clearance in septic patients | |
|
Dose adjustment or drug discontinuation in case of side effects | |
|
Drug dosing in special populations (elderly, obesity, pregnancy, pediatrics, …) | |
| Anticoagulation |
Assessing thromboprophylaxis for patients |
|
Monitoring of anticoagulants efficacy | |
|
Managing side effects and interactions related to anticoagulation | |
|
Assessing the indication for stress ulcer prophylaxis | |
|
Assessing the indications and contraindications for the use of different anticoagulants, including direct oral anticoagulants |
Figure 3The clinical decision‐making and sharing of information flow
Information that can be shared between different hospitals
| Information about new drugs indications for COVID‐19 |
| Protocols for appropriate and rational use of drugs |
| Protocols for the administration of drugs |
| Protocols for managing common drug‐related problems (ADR, drug‐drug interactions, …) |
| Patient education materials |